Can COVID-19 cause diabetes?

Accili, Domenico

doi:10.1038/s42255-020-00339-7

Cited by 120 publications

(124 citation statements)

References 20 publications

Supporting

Mentioning

110

Contrasting

Unclassified

Order By: Relevance

“…Overall, there is currently not supporting evidence of an increase in incidence of Type 1 diabetes cases associated with the current pandemic. [85][86][87] Data surrounding T2D have shown some effects on glycemic control at diagnosis, but this may also be related to lifestyle changes as a consequence of lockdown. [88][89][90] Identification of "new" diabetes also has the potential to be confounded by preexisting undiagnosed disease (especially in T2D, which can be insidious in onset).…”

Section: The Impact Of the Covid-19 Pandemic On The Incidence Of Diabetes During The Pandemicmentioning

confidence: 99%

Not so sweet and simple: impacts of SARS-CoV-2 on the β cell

Ibrahim

Monaco

Sims

2021

Islets

View full text Add to dashboard Cite

The link between COVID-19 infection and diabetes has been explored in several studies since the start of the pandemic, with associations between comorbid diabetes and poorer prognosis in patients infected with the virus and reports of diabetic ketoacidosis occurring with COVID-19 infection. As such, significant interest has been generated surrounding mechanisms by which the virus may exert effects on the pancreatic β cells. In this review, we consider possible routes by which SARS-CoV-2 may impact β cells. Specifically, we outline data that either support or argue against the idea of direct infection and injury of β cells by SARS-CoV-2. We also discuss β cell damage due to a "bystander" effect in which infection with the virus leads to damage to surrounding tissues that are essential for β cell survival and function, such as the pancreatic microvasculature and exocrine tissue. Studies elucidating the provocation of a cytokine storm following COVID-19 infection and potential impacts of systemic inflammation and increases in insulin resistance on β cells are also reviewed. Finally, we summarize the existing clinical data surrounding diabetes incidence since the start of the COVID-19 pandemic.

show abstract

Section: The Impact Of the Covid-19 Pandemic On The Incidence Of Diabetes During The Pandemicmentioning

confidence: 99%

Not so sweet and simple: impacts of SARS-CoV-2 on the β cell

Ibrahim

Monaco

Sims

2021

Islets

View full text Add to dashboard Cite

show abstract

“…Still it is a subject of discussion if COVID-19 can indeed cause new-onset diabetes or accelerate pre-existing diabetes or prediabetes 19 . Based on observations that beta-cells do not express virus receptors such as ACE2 20 – 22 , a direct involvement of virus on beta-cells has been considered unlikely.…”

Section: Introductionmentioning

confidence: 99%

Viral infiltration of pancreatic islets in patients with COVID-19

et al. 2021

View full text Add to dashboard Cite

Metabolic diseases are associated with an increased risk of severe COVID-19 and conversely, new-onset hyperglycemia and complications of preexisting diabetes have been observed in COVID-19 patients. Here, we performed a comprehensive analysis of pancreatic autopsy tissue from COVID-19 patients using immunofluorescence, immunohistochemistry, RNA scope and electron microscopy and detected SARS-CoV-2 viral infiltration of beta-cells in all patients. Using SARS-CoV-2 pseudoviruses, we confirmed that isolated human islet cells are permissive to infection. In eleven COVID-19 patients, we examined the expression of ACE2, TMPRSS and other receptors and factors, such as DPP4, HMBG1 and NRP1, that might facilitate virus entry. Whereas 70% of the COVID-19 patients expressed ACE2 in the vasculature, only 30% displayed ACE2-expression in beta-cells. Even in the absence of manifest new-onset diabetes, necroptotic cell death, immune cell infiltration and SARS-CoV-2 viral infection of pancreatic beta-cells may contribute to varying degrees of metabolic dysregulation in patients with COVID-19.

show abstract

“…To complicate this scenario further, COVID-19 may cause diabetes by inducing hyper-inflammation, directly infecting pancreatic endocrine cells, leading to impaired insulin secretion [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

Managing diabetes in diabetic patients with COVID: where do we start from?

2021

View full text Add to dashboard Cite

Aims COVID-19 has and still is sweeping away the national health systems worldwide. In this review, we sought to determine the evidence base proofs on the antidiabetic treatment capable to reduce the risk of COVID-19-related mortality. Methods We have performed a systematic search of published articles using PubMed, and EMBASE from March 2020 to March 31st, 2021. We excluded editorials, commentary, letters to the editor, reviews, and studies that did not have mortality as an outcome. For metformin and insulin only, we performed a meta-analysis using Cochrane RevMan 5.2. Results Among antidiabetic drugs, metformin was the only drug associated with a reduced risk of mortality. Conversely, insulin appears associated with an increased risk. The other classes of drugs were neutral. Conclusions The totality of articles reports retrospective data strongly affected by “channeling bias” so that most of the existing results on each class of drugs are driven by the phenotype of patients likely to receive that specific drug by prescription.

show abstract

Can COVID-19 cause diabetes?

Cited by 120 publications

References 20 publications

Not so sweet and simple: impacts of SARS-CoV-2 on the β cell

Not so sweet and simple: impacts of SARS-CoV-2 on the β cell

Viral infiltration of pancreatic islets in patients with COVID-19

Managing diabetes in diabetic patients with COVID: where do we start from?

Contact Info

Product

Resources

About